Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2024-01-01 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - SNT 6 pages 27.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). This is a regulatory announcement related to capital changes but is not a full financial report or earnings release. It fits the category of Share Issue/Capital Change announcements, as it concerns new securities being quoted following option exercises.
2024-01-01 English
Syntara Receives $5m R&D Tax Incentive 2 pages 496.4KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 5 December 2023 from Syntara Limited (formerly Pharmaxis Ltd) announcing receipt of an R&D tax incentive for the 2023 financial year and providing updates on the company's clinical development pipeline and financial position. It includes forward-looking statements and company background information. The document is short (4870 characters) and is clearly a press release or announcement rather than a detailed financial report or regulatory filing. It does not contain financial statements, audit information, management discussion, or detailed investor presentation content. It is not an earnings release or interim report. The content focuses on a tax incentive announcement and company updates, typical of a regulatory announcement or media release. Given the nature and length, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-12-04 English
Change of Company Name 2 pages 491.4KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing the Australian Securities and Investment Commission's issuance of a Certificate of Registration for a company name change from Pharmaxis Ltd to Syntara Limited. It references the approval of this change at the 2023 annual general meeting and mentions the change of the ASX code. The document is short (4446 characters) and primarily serves as an announcement of a corporate action (name change) following shareholder approval. It does not contain financial statements, detailed financial performance, or substantive financial data. It is not a report itself but an announcement related to a corporate event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-03 English
Notification regarding unquoted securities - PXS 6 pages 28.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically performance rights issued under an employee incentive scheme. It details the number of securities issued, the date of issue, and mentions key management personnel involved. The document is an announcement of a capital change event related to securities issuance, not a full financial report or earnings release. It fits the category of announcements about new share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a report publication announcement or regulatory filing but a substantive announcement of capital changes.
2023-11-28 English
Change of Director's Interest Notice - GP 2 pages 271.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options held before and after the change, nature of the change, and dates. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3355 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or other financial report type. Therefore, the correct classification is Director's Dealing (DIRS).
2023-11-28 English
Chair's Address to Shareholders 2 pages 170.7KB
AGM Information Classification · 95% confidence The document is a speech given by the Chair of Pharmaxis Ltd at the Annual General Meeting (AGM) held on 28 November 2023. It includes an introduction by the new Chair, discussion of company strategy, pipeline focus, and acknowledgments to outgoing directors and employees. The content is typical of AGM presentations or addresses, focusing on company direction and leadership changes rather than detailed financial data or regulatory disclosures. The document length is 3730 characters, which is relatively short and consistent with an AGM address rather than a full annual report or other detailed filings. Therefore, the document fits best into the category of AGM Information (AGM-R).
2023-11-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.